Early onset of fesoterodine efficacy in subjects with overactive bladder

BJU International

Volumn 107, Issue 4, 2011, Pages 598-602

  Goldman, Howard B ^a   Morrow, Jon D ^b   Gong, Jason ^b   Tseng, Li Jung ^b   Schneider, Tim ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c Praxisklinik Urologie Rhein Ruhr   (Germany)

Author keywords

antimuscarinic; efficacy; fesoterodine; open label; overactive bladder

Indexed keywords

FESOTERODINE; TOLTERODINE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 79551517875     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09586.x     Document Type: Article

References (29)

1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49
3. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 1044-50
4. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L,. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006; 97: 96-100
5. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I,. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388-95
6. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94
7. DetrolA LA, (tolterodine tartrate). Full Prescribing Information. New York, NY: Pfizer Inc, 2008
8. Toviaza, (fesoterodine fumarate). Full Prescribing Information. New York, NY: Pfizer Inc, 2008
9. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12
10. Nitti V, Dmochowski R, Sand P, et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol 2007; 178: 2488-94
11. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010; 105: 58-66
12. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009; 63: 560-7
13. Coyne KS, Tubaro A, Brubaker L, Bavendam T,. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68: 9-16
14. Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P,. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 2008; 27: 179-90
15. Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z,. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008; 24: 3513-21
16. Siami P, Seidman LS, Lama D,. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 616-28
17. Sussman DO, Kraus SR, Carlsson M, Guan Z,. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007; 23: 777-81
18. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S,. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5
19. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R,. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006; 97: 540-6
20. Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 1120-7
21. Cawello W, Auer S, Hammes W, Sachse R, Horstmann R,. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002; 365: R110
22. Michel MC,. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 1787-96
23. Malhotra B, Guan Z, Wood N, Gandelman K,. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 556-63
24. Nilvebrant L,. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11: 13-27
25. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J,. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998; 63: 529-39
26. Stahl MM, Ekstrom B, Sparf B, Mattiasson A, Andersson KE,. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14: 647-55
27. van Leeuwen JHS, Castro R, Busse M, Bemelmans BL,. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50: 440-53
28. Lee S, Malhotra B, Creanga D, Carlsson M, Glue P,. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 2009; 9: 55
29. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z,. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008; 71: 839-43